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The therapeutic landscape of chronic
myeloid leukemia (CML) has changed dra-
matically in the last decade (1). In par-
ticular, the availability of imatinib mesy-
late, a tyrosine kinase inhibitor (TKI) tar-
geting BCR–ABL, has led to profound
and durable remissions in the majority
of patients. However, a significant propor-
tion of patients either present with primary
resistance to imatinib or develop secondary
resistance sooner or later during treat-
ment. Therefore, second-generation TKIs
have been introduced, including nilotinib.
In fact, genetic mutations in BCR–ABL
result in several possible changes and lead
to subsequent TKI resistance (2). It is
known that the most cases of CML are
characterized by a BCR–ABL fusion pro-
tein originating from the t(9;22) chromo-
somal translocation. The exact breakpoint
of the translocation and the molecular
weight of the resulting fusion gene pro-
tein vary. Mostly, the breakpoint on chro-
mosome 22, falling in the so-called major
breakpoint cluster region between exons
13 and 14 of the BCR gene (M-bcr), leads
to a hybrid BCR–ABL mRNA with a b2a2
or b3a2 junction, which encodes a p210
fusion protein associated with the under-
lying mechanism, in the chronic phase
of CML (3). Cases of CML with break-
points in other regions are seen in other
regions, namely minor (m-bcr) and micro
(µ-bcr) bcr region, but to date, these cases
are few in number. In particular, the µ-
bcr breakpoint connects exon 19 of BCR
with ABL (exon 2 of which is the joining
point in all three cases), giving rise to the
e19a2 transcript corresponding to the p230
fusion protein. The e19a2 rearrangement
was detected in patients with typical CML
or in those with a rather aggressive clini-
cal course (4). However, our experience has
given us great hopes for the future. In fact,
a 39-year-old male patient was diagnosed
with chronic phase CML in March 2012.
The examination of his peripheral blood
showed a hemoglobin level of 12.6 g/dL,
mean corpuscular volume of 112 fL, white
blood cell count of 58× 109/L (with dif-
ferential counts neutrophils 41%, lympho-
cytes 0%, monocytes 0%, eosinophils 0.5%,
basophils 0.9%, myeloblasts 2%, myelo-
cytes 29%, metamyelocytes 20%), and a
platelet count of 212× 109/L. After bone
marrow aspirate, the cytogenetic analysis
revealed 46, XY, t(9;22)(q34;q11.2) kary-
otype in 100% of metaphase. The quan-
titative reverse transcription polymerase
chain reaction (RQ-PCR) detected the
sole presence of the e19a2 transcript.
After starting frontline treatment with
nilotinib 600 mg/day (April 2012), the
patient achieved a complete cytogenetic
response (after 4 months) and complete
molecular response (CMR), defined as the
absence of detectable BCR–ABL transcript
by RQ-PCR (after 6 months). Currently,
18 months after the start of the treatment,
the patient continues to take 600 mg nilo-
tinib per day and CMR is confirmed. We
have found only two reporting data on
nilotinib treatment in patients with the
e19a2 rearrangement (5, 6). Interestingly,
the use of nilotinib has induced a fast CMR
also in our patient who maintained a CMR
for over 1 year until today. It is mandatory
to improve our ability to predict outcomes
in our patients using ad hoc molecular
tests (DNA sequencing and gene expres-
sion profiling), in order to offer the optimal
strategy to individual patients. In our expe-
rience, we recommend the use of nilotinib
as frontline agent for the treatment of this
CML variant, according to the evidence
of a deep and rapid molecular response
obtained in our patient.
In addition, accurate clinicobiological
evaluation, an evidence-based approach,
and identification of potential biomarkers
are definitely warranted to delineate the
best approach in a given case.
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